Sandoz Group AG

Sandoz is a global leader in generic pharmaceuticals and biosimilars, committed to pioneering access for patients by developing and commercializing high-quality, affordable medicines. Formerly a division of Novartis, Sandoz successfully spun off as an independent, publicly traded company in October 2023. The company holds a leading position in several therapeutic areas, including immunology, oncology, and endocrinology. Sandoz operates with a massive global footprint, serving over 100 markets and reaching approximately 500 million patients annually. Its business strategy is heavily focused on the 'Golden Decade' of biosimilars, aiming to capture a significant share of the $400 billion in biologics expected to lose exclusivity by 2030. The company is currently investing heavily in European manufacturing, particularly in Slovenia and France, to secure its supply chain.